Skip to main content
Gut logoLink to Gut
. 1979 Mar;20(3):186–189. doi: 10.1136/gut.20.3.186

Liver damage associated with perhexiline maleate.

D Lewis, H C Wainwright, M C Kew, S Zwi, C Isaacson
PMCID: PMC1412298  PMID: 437550

Abstract

Two patients who developed biochemical and histological evidence of hepatitis while taking the anti-anginal drug perhexiline maleate are described. The pathological changes were those of mild to moderate fatty change together with a hepatitis which resembled alcoholic hepatitis, including in one patient the presence of material which by light microscopy was indistinguishable from Mallory's alcoholic hyalin. However, the predominantly periportal location of this material contrasted with the centrilobular distribution of Mallory's hyaline. One patient showed, in addition, severe atypia of the hepatocytes which was still present in less pronounced form 10 weeks after stopping perhexiline. The other patient had advanced hepatic fibrosis.

Full text

PDF
186

Images in this article

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abaza A., Cattan D., Aziza C., Pappo E. Lettre: Effets secondaires mais réversibles á la prise de perhexiline. Nouv Presse Med. 1973 Nov 24;2(42):2820–2820. [PubMed] [Google Scholar]
  2. Anthony P. P. Primary carcinoma of the liver: a study of 282 cases in Ugandan Africans. J Pathol. 1973 May;110(1):37–48. doi: 10.1002/path.1711100105. [DOI] [PubMed] [Google Scholar]
  3. Beaugrand M. Hépatite médicamenteuse à la perhexilline. Nouv Presse Med. 1976 Jul 3;5(27):1695–1695. [PubMed] [Google Scholar]
  4. Feldman G. Hypoglycémie et perhexilline. 1974 Nov 30-Dec 14Nouv Presse Med. 3(41-43):2580–2580. [PubMed] [Google Scholar]
  5. Kopelman P., Morgan P. G. Liver damage after perhexiline maleate. Lancet. 1977 Mar 26;1(8013):705–705. doi: 10.1016/s0140-6736(77)92149-3. [DOI] [PubMed] [Google Scholar]
  6. Lageron A., Poupon R., de Saint-Maur P. P., Lévy V. G. Liver ganglioside storage after perhexiline maleate. Lancet. 1977 Feb 26;1(8009):483–483. doi: 10.1016/s0140-6736(77)91967-5. [DOI] [PubMed] [Google Scholar]
  7. Lhermitte F., Fardeau M., Chedru F., Mallecourt J. Polyneuropathy after perhexiline maleate therapy. Br Med J. 1976 May 22;1(6020):1256–1256. doi: 10.1136/bmj.1.6020.1256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Lockhart J. D., Masheter H. C. Letter: Perhexiline maleate in angina pectoris. Br Med J. 1976 Jun 19;1(6024):1530–1531. doi: 10.1136/bmj.1.6024.1530-b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Long-term perhexiline maleate and liver function. Br Med J. 1976 Jan 17;1(6002):133–133. doi: 10.1136/bmj.1.6002.133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. McDonald G. S. Liver damage after perhexiline maleate. Lancet. 1977 May 14;1(8020):1056–1056. doi: 10.1016/s0140-6736(77)91290-9. [DOI] [PubMed] [Google Scholar]
  11. Newberne J. W. Proceedings: Assessment of safety data from patients on short and long-term perhexiline therapy. Postgrad Med J. 1973 Apr;49(Suppl):125–132. [PubMed] [Google Scholar]
  12. Pilcher J., Chandrasekhar K. P., Rees J. R., Boyce M. J., Peirce T. H., Ikram H. Proceedings: Long-term assessment of perhexiline maleate in angina pectoris. Postgrad Med J. 1973 Apr;49(Suppl):115–118. [PubMed] [Google Scholar]
  13. Roger P., Nogue F., Ragnaud J. M., Manciet G., Doumax Y. Hypoglycémie après maléate de perhexiline. Nouv Presse Med. 1975 Nov 1;4(37):2663–2663. [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES